Back to Agenda
Session 5: Hot Topics - Bitesized Updates
Session Chair(s)
Vicki Edwards, RPH
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
Willemijn van der Spuij, MSC
Executive Director Europe | International - Patient Safety, Bristol Myers Squibb, Switzerland
The Hot Topics session provides insights in the very latest on discussions in specific Safety areas of interest. Experts will address the latest on topics that are being discussed by the Industry Trade Association (EFPIA - should we be more global?) and Regulatory Authorities and will therefore give the audience an insight in the key topics of the moment. The expert speakers that lead these discussions will share information on these key topics, the issues at hand, the progress that is being made and what the audience can expect on these topics for the future. The topics will be of interest to a broad audience and will be of specific value to participants that are not able to attend Industry Association meetings or public meetings with EMA due to limited attendance possibilities.
This session offers a great opportunity to hear about these topics from experts in the field. The audience can expect different exciting presentations that will please the crowd.
And in face to face format!
Speaker(s)
David John Lewis, PHD
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance, Novartis Pharma Gmbh, Switzerland
ICH E2D
Vicki Edwards, RPH
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
EMA Digital Risk Minimisation Initiative
Guy Demol
EU QPPV, MSD, Belgium
PASS
Vicki Edwards, RPH
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
EMA Industry Platform Meeting: PSUR NAPs and RMP vs Summary
Vicki Edwards, RPH
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
Quick Updates: Prolongation EV signaling
Guy Demol
EU QPPV, MSD, Belgium
Quick Updates: E19
David John Lewis, PHD
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance, Novartis Pharma Gmbh, Switzerland
Quick Updates: IMI
Have an account?